Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Singh Moodley, Ashika ^a   Perovic, Olga ^a,b  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antimicrobial susceptibility testing; Carbapenemase producing Enterobacteriaceae; Carbapenemases; Resistance genes

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTAZIDIME; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE; CARBAPENEMASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BLAGES GENE; BLAIMP GENE; BLAKPC GENE; BLANDM GENE; BLAOXA 48 GENE; BLAVIM GENE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CITROBACTER FREUNDII; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; GENETIC SCREENING; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PREDICTIVE VALUE; PREVALENCE; PROTEUS MIRABILIS; SENSITIVITY AND SPECIFICITY; SERRATIA MARCESCENS; SOUTH AFRICA; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ENTEROBACTERIACEAE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS; REAL-TIME POLYMERASE CHAIN REACTION; SOUTH AFRICA;

EID: 84991608307     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1858-7     Document Type: Article

References (37)

1. Gupta N, et al. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60-7.
2. Spellberg B, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155-64.
3. Kocsis B, Szabó D. Antibiotic resistance mechanisms in Enterobacteriaceae. Microbial pathogens and strategies for combating them: science, technology and education. Vol. 1 ISBN: 978-84-939843-9-7. 2013: Formatex Research Center.
4. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333-41.
5. Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care. 2007;13(5):592-7.
6. Falagas ME, et al. Antibiotic treatment of infections due to carbapenemresistant enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654-63.
7. Livermore DM. My CRE is a CPO, is yours?, in Public Health England, Antimicrobial Resistance and Healthcare Associated Infections Reference Unit (AMRHAI) News. UK: 2013. PHE publications gateway number: 2013137.
8. Queenan AM, Bush K. Carbapenemases: the Versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440-58.
9. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 2006;14(9):413-20.
10. Rodriguez-Martinez JM, et al. Plasmid-mediated quinolone resistance: an update. J Infect Chemother. 2011;17(2):149-82.
11. Rodriguez-Martinez JM, et al. VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010;54(1):471-6.
12. Fernández-Cuenca F, et al. Production of a plasmid-encoded OXA-72 β-lactamase associated with resistance to carbapenems in a clinical isolate Acinetobacter junii. Int J Antimicrob Agents. 2012;39(1):93-4.
13. Carrer A, et al. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother. 2008;52(8):2950-4.
14. Cuzon G, Bonnin RA, Nordmann P. First identification of novel NDM carbapenemase, NDM-7, in Escherichia coli in France. PLoS One. 2013;8(4):e61322.
15. Gottig S, et al. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-beta-lactamase with increased carbapenemase activity. J Antimicrob Chemother. 2013;68(8):1737-40.
16. Hayakawa K, et al. Molecular and epidemiological characterization of iMPtype metallo-beta-lactamase-producing enterobacter cloacae in a Large Tertiary Care Hospital in Japan. Antimicrob Agents Chemother. 2014;58(6): 3441-50.
17. Hornsey M, Phee L, Wareham DW. A novel variant, NDM-5, of the New Delhi metallo-beta-lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom. Antimicrob Agents Chemother. 2011;55(12):5952-4.
18. Koh TH, Wang GCY, Sng L. IMP-1 and a novel metallo-beta-lactamase, VIM-6, in fluorescent pseudomonads isolated in Singapore. Antimicrob Agents Chemother. 2004;48(6):2334-6.
19. Leung GHY, et al. Persistence of related bla-IMP-4 metallo-betalactamase producing Enterobacteriaceae from clinical and environmental specimens within a burns unit in Australia-a six-year retrospective study. Antimicrob Resist Infect Control. 2013;2(35). doi: 10.1186/2047-2994-2-35.
20. Patzer JA, et al. Emergence and persistence of integron structures harbouring VIM genes in the Children's Memorial Health Institute, Warsaw, Poland, 1998-2006. J Antimicrob Chemother. 2009;63(2):269-73.
21. Poirel L, et al. Emergence of metallo-beta-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob Agents Chemother. 2010;54(11):4914-6.
22. Richter SN, et al. Transfer of KPC-2 Carbapenemase from Klebsiella pneumoniae to Escherichia coli in a patient: first case in Europe. J Clin Microbiol. 2011;49(5):2040-2.
23. Robin F, et al. Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. Antimicrob Agents Chemother. 2010;54(1):466-70.
24. Shet V, et al. IMP metallo-beta-lactamase-producing clinical isolates of Enterobacter cloacae in the UK. J Antimicrob Chemother. 2011;66(6):1408-9.
25. Yong D, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046-54.
26. Zarfel G, et al. Carbapenemases in Enterobacteria, Hong Kong, China, 2009. Emerg Infect Dis. 2011;17(1):130-1.
27. Brink AJ, et al. Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J Clin Microbiol. 2011;50(2):525-7.
28. Govind C, et al. NDM-1 imported from India-first reported case in South Africa. SAMJ. 2013;103(7):476-8.
29. Brink AJ, et al. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol. 2013;51(1):369-72.
30. Lowman W, et al. NDM-1 has arrived: First report of carbapenem resistance mechanism in South Africa. SAMJ. 2011;101(12):873-5.
31. Jacobson RK, et al. Molecular Characterisation and Epidemiolgical Investigation of an Outbreak of blaOXA-181 carbapenemase-producing isolates of Klebsiella pneumoniae in South Africa. SAMJ. 2015;105(12):1030-5.
32. Singh-Moodley A, Ekermans P, Perovic O. Emerging Carbapenem-Resistant Enterobacter cloacae Producing OXA-48-, VIM-and IMP-Type-β-lactamases in Eastern Cape Hospitals in South Africa. Open J Med Microbiol. 2015;5:246-53.
33. Chea N, et al. Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae. Emerg Infect Dis. 2015;21(9):1611-6.
34. Clinical and Laboratory Standards Institute (CLSI) guidelines-Performance Standards for Antimicrobial Susceptibility Testing. in CLSI document M100. 2016.
35. Brink A, et al. The speread of carbapenem-resistant Enterobacteriaceae in South Africa: Risk factors for acquisition and prevention. S Afr Med J. 2012;102(7):599-601.
36. Docquier JD, et al. On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother. 2003;51:257-66.
37. Tato M, et al. Carbapenem Heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J Clin Microbiol. 2010;48(11):4089-93.